Molecules that bind to cd94/nkg2a heterodimer polypeptides
US-2024415889-A1 · Dec 19, 2024 · US
Compositions and methods for detecting EGFR in cancer
US10000568B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10000568-B2 |
| Application number | US-45045709-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 10, 2009 |
| Priority date | Apr 10, 2008 |
| Publication date | Jun 19, 2018 |
| Grant date | Jun 19, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A purified antibody that specifically binds an epidermal growth factor receptor (EGFR) comprising a deletion at position E746-A750, wherein said antibody comprises a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 9, 10, and 11 respectively, and a light chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18 respectively. 2. A purified antibody that specifically binds an epidermal growth factor receptor (EGFR) comprising a deletion at position E746-A750, wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 81. 3. The antibody of claim 2 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 82. 4. A purified antibody that specifically binds an epidermal growth factor receptor (EGFR) comprising a deletion at position E746-A750, wherein said antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 82. 5. A purified antibody that specifically binds an epidermal growth factor receptor (EGFR) comprising a deletion at position E746-A750, wherein the heavy chain of the antibody comprises SEQ ID NO: 2 and the light chain of the antibody comprises SEQ ID NO: 4.
Assignees
Inventors
Classifications
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
- C07K16/2863Primary
against receptors for growth factors, growth regulators · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title
Inhibitors; Suppressors · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10000568B2 cover?
- The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.
- Who is the assignee on this patent?
- Gu Ting Lei, Wu Jiong, Kane Susan, and 6 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).